# Acamprosate and Methazolamide for Essential Tremor

> **NCT06312800** · PHASE2 · WITHDRAWN · sponsor: **Henry Ford Health System**

## Conditions studied

- Essential Tremor

## Interventions

- **DRUG:** Acamprosate
- **DRUG:** Placebo
- **DRUG:** Methazolamide

## Key facts

- **NCT ID:** NCT06312800
- **Lead sponsor:** Henry Ford Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-03
- **Primary completion:** 2017-06
- **Final completion:** 2017-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was never initiated.
- **Last updated:** 2024-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06312800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06312800, "Acamprosate and Methazolamide for Essential Tremor". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06312800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*